Navigation Links
The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference
Date:2/10/2009

The 2009 Personalized Medicine Conference is bringing together the wide variety of stakeholders in both the public and private sector to examine both the opportunities and challenges facing those involved in the development and realization of personalized medicine.

Baltimore, MD (PRWEB) February 10, 2009 -- Arrowhead's 2009 Personalized Medicine Conference is a full two day conference set to take place in Baltimore on April 23rd and 24th that will bring together leaders from industry, government and academia to discuss issues of central importance to the future of personalized medicine. Sessions will be held on a variety of topics integral to the development of personalized medicine, including, but not limited to:

- pharmacogenomics
- biomarkers
- molecular diagnostics
- pharmacogenetics

Sessions will not only cover the various scientific and clinical developments in this space, but also a plethora of other issues that will need to be resolved in order to ensure success in this field, including:

- future regulatory models for personalized medicine
- social, ethical and legal concerns
- economic issues (insurance coverage, reimbursement, etc.)

Patrick Terry, the Co-Founder of Genomic Health and the Founder of the Personalized Medicine Coalition will share with attendees how innovative diagnostic companies are securing value-based rather than cost-based payment and will discuss how these innovators are building compelling clinical and economic evidence to support coverage and value-based payment from payers.

Attendees will also hear from Robert L. Becker, Jr, MD, Ph.D, the Chief Medical Officer of the FDA's Office of In Vitro Diagnostic Device Evaluation and Safety on the role of laboratory tests in personalized medicine and from Asif Dhar, MD, MBA, a Senior Fellow at the Deloitte Center for Health Solutions on the issue of ROI in targeted therapies. Specifically, Dr. Dhar will discuss the barriers facing developers of personalized medicine as well as the benefits of adopting personalized medicine.

Twenty five other speakers will be on hand to discuss the following issues:

- value creation in personalized medicine
- financial transparency in personalized medicine
- private insurance and Medicare coverage of personalized medicine
- the payors' perspective on personalized medicine
- the role of biomarkers and molecular diagnostics in the future of medicine
- how personalized medicine is faring in clinical trials
- perspectives on how clinicians will use personalized therapies in the future
- the role of health information technology and informatics in personalized medicine
- legal, regulatory and ethical concerns facing developers of personalized medicine
- personalized medicine business models and market analysis

See Agenda

Other key speakers:

Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement, ex-officio member, Secretary's Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Keith Batchelder, MD, Chief Executive Officer and Founder, Genomic Healthcare Strategies
Colin Brenan, Ph.D., Chief Technology Officer, VP Business Development, Co-Founder, BioTrove, Inc.
Teresa DeLuca, MD, Vice President Dept of Personalized Medicine, Medco
Professor Herbert A. Fritsche Jr., Ph.D., Professor & Chief of Clinical Chemistry, University of Texas M. D. Anderson Cancer Center
David Lester, Executive Vice President, Corporate Development, Gene Express Inc.
Thomas Metcalfe, Ph.D., Head, Personalized Healthcare Portfolio, F. Hoffmann-La Roche Ltd.
Bruce Quinn, MD, Ph.D., Senior Health Policy Specialist, Foley and Hoag
Rebekah Rasooly, Program Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH)
Wayne Roe, Director, Celera Diagnostics, Director, In-Cube Ventures
Mollie Roth, Esq., Corporate Counsel, VP Business Development, Diaceutics
Surya Singh, M.D., Chief Medical Officer and Vice President of Clinical Development, Proventys, Inc.
Grail Sipes, Partner, Covington & Burling, Food and Drug Practice and Life Sciences Industry Group

For more information about this conference, please visit http://www.arrowheadpublishers.com or call 1-312-244-3703.

###

Read the full story at http://www.prweb.com/releases/personalizedmedicine/pharmacogenomics/prweb2002114.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
2. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
3. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
4. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
5. Neogen Names New Senior Science Officer; Added to S&P Index
6. Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer
7. NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations
8. Cequent Names Ted Hibben Chief Business Officer
9. Clarus Ventures Names Two New Partners
10. Xceleron Names Michael Butler as President & CEO
11. Genome Technology Names 2008 Tomorrows PIs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):